title: Primary hormonal treatment for early endometrial carcinoma.
abstract: Four cases of clinical Stage I endometrial carcinoma initially treated with hormonal therapy are included in this study. Three of them resulted in tumor regression and two of them permitted a subsequent three pregnancies. All patients are alive and without evidence of disease with a median follow-up of 35.7 months (range 17 to 72 months). We believe this is a promising approach through which we may be able to offer a conservative treatment maintaining high survival rates and preserving childbearing potential. Diagnostic and therapeutic data for fertility-desiring patients with endometrial carcinoma are analyzed in this study.
authors.affiliation: Gynecologic Oncology Unit, General Jose de San Martin Hospital, Buenos Aires University, Argentina.
authors.forename: J
authors.initials: J
authors.lastname: Sardi
authors.forename: J P
authors.initials: JP
authors.lastname: Anchezar Henry
authors.forename: G
authors.initials: G
authors.lastname: Paniceres
authors.forename: N
authors.initials: N
authors.lastname: Gomez Rueda
authors.forename: S
authors.initials: S
authors.lastname: Vighi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001707:Biopsy, Needle; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate